Qube Research & Technologies LTD Cyma Bay Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.63 - $24.47 $1.68 Million - $3.25 Million	132,809 New	132,809 $3.14 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $425,817 - $694,488	-72,418 Reduced 78.63%	19,687 $171,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $103,300 - $201,147	32,081 Added 53.45%	92,105 $577,000
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $115,957 - $177,913	41,862 Added 230.49%	60,024 $210,000
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $31,238 - $61,569	18,162 New	18,162 $54,000
Q1 2021 May 14, 2021	SELL	$4.23 - $6.55 $95,843 - $148,409	-22,658 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $228,735 - $360,468	-39,919 Reduced 63.79%	22,658 $130,000
Q3 2020 Nov 12, 2020	BUY	$3.32 - $7.24 $173,948 - $379,332	52,394 Added 514.52%	62,577 $453,000
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $14,358 - $43,277	10,183 New	10,183 $36,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.